| Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant’Angelo, J Forman, ... Nature medicine 26 (6), 909-918, 2020 | 586 | 2020 |
| Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation AF Correa, O Jegede, NB Haas, KT Flaherty, MR Pins, EM Messing, ... Journal of Clinical Oncology 37 (23), 2062, 2019 | 98 | 2019 |
| irRECIST for the evaluation of candidate biomarkers of response to nivolumab in metastatic clear cell renal cell carcinoma: analysis of a phase II prospective clinical trial JC Pignon, O Jegede, SA Shukla, DA Braun, CE Horak, M Wind-Rotolo, ... Clinical Cancer Research 25 (7), 2174-2184, 2019 | 88 | 2019 |
| KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1 RS Bhatt, A Berjis, JC Konge, KM Mahoney, AN Klee, SS Freeman, ... Cancer immunology research 9 (2), 156-169, 2021 | 71 | 2021 |
| A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma AH Nassar, KW Mouw, O Jegede, AB Shinagare, J Kim, CJ Liu, ... British journal of cancer 122 (4), 555-563, 2020 | 66 | 2020 |
| Phase II study of nivolumab and salvage nivolumab+ ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)(HCRN GU16-260). MB Atkins, O Jegede, NB Haas, DF McDermott, MA Bilen, CG Drake, ... Journal of Clinical Oncology 38 (15_suppl), 5006-5006, 2020 | 65 | 2020 |
| Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma M Ficial, OA Jegede, M Sant'Angelo, Y Hou, A Flaifel, JC Pignon, ... Clinical Cancer Research 27 (5), 1371-1380, 2021 | 53 | 2021 |
| Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, ... Journal of Clinical Oncology 40 (25), 2913, 2022 | 41 | 2022 |
| Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. IE Krop, O Jegede, JE Grilley-Olson, JD Lauring, SR Hamilton, JA Zwiebel, ... Journal of Clinical Oncology 36 (15_suppl), 101-101, 2018 | 40 | 2018 |
| Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma AF Correa, OA Jegede, NB Haas, KT Flaherty, MR Pins, A Adeniran, ... European urology 80 (1), 20-31, 2021 | 39 | 2021 |
| Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial MM Regan, OA Jegede, CM Mantia, T Powles, L Werner, RJ Motzer, ... Clinical Cancer Research 27 (24), 6687-6695, 2021 | 38 | 2021 |
| Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805 … Z Lee, OA Jegede, NB Haas, MR Pins, EM Messing, J Manola, CG Wood, ... The Journal of urology 203 (4), 684-689, 2020 | 31 | 2020 |
| Cardiovascular complications in COVID‐19 patients with or without diabetes mellitus T Abe, O Egbuche, J Igwe, O Jegede, B Wagle, T Olanipekun, ... Endocrinology, Diabetes & Metabolism 4 (2), e00218, 2021 | 26 | 2021 |
| ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R)±lenalidomide (L) consolidation for Mantle cell lymphoma … MR Smith, O Jegede, P Martin, BG Till, SS Parekh, DT Yang, L Kostakoglu, ... Journal of Clinical Oncology 39 (15_suppl), 7503-7503, 2021 | 20 | 2021 |
| Minimal residual disease (MRD) assessment in the ECOG1411 randomized phase 2 trial of front-line bendamustine-rituximab (BR)-based induction followed by rituximab (R … M Smith, O Jegede, S Parekh, CA Hanson, P Martin, BG Till, M Crump, ... Blood 134, 751, 2019 | 19 | 2019 |
| 713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214 M Regan, OA Jegede, C Mantia, T Powles, L Werner, S Huo, V Del Tejo, ... Annals of Oncology 31, S561, 2020 | 15 | 2020 |
| Arterial spin labeled perfusion MRI for the evaluation of response to tyrosine kinase inhibition therapy in metastatic renal cell carcinoma LL Tsai, RS Bhatt, MF Strob, OA Jegede, MRM Sun, DC Alsop, ... Radiology 298 (2), 332-340, 2021 | 14 | 2021 |
| Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial … IE Krop, OA Jegede, JE Grilley-Olson, JD Lauring, EP Mitchell, JA Zwiebel, ... JCO precision oncology 6, e2100424, 2022 | 13 | 2022 |
| NCI-MATCH arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (Mut/del) or PTEN protein loss F Janku, O Jegede, SL Puhalla, P Konstantinopoulos, F Meric-Bernstam, ... Annals of Oncology 29, viii137, 2018 | 11 | 2018 |
| Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell … JC Pignon, O Jegede, KM Mahoney, RB Moreira, J Novak, H Conen, ... Journal of Clinical Oncology 35 (6_suppl), 477-477, 2017 | 10 | 2017 |
Michael AtkinsGeorgetown-Lombardi Comprehensive Cancer CtrVerified email at georgetown.edu
